BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.66) per share. This is a 35.92 percent increase over losses of $(1.03) per share from the same period last year.
Seagen Reports Data From SEA-CD40 In Combination With Other Therapies In Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) At American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Seagen Inc. (NASDAQ:SGEN) today announced data from a phase 1 clinical trial combining SEA-CD40 with chemotherapy and an anti-PD-1 in patients with metastatic PDAC at the ASCO GI annual meeting taking place in San
